Fig. 6: BTK inhibitor Acalabrutinib promotes the anti-proliferative effects of Gefitinib/Osimertinib in Gefitinib-sensitive PC-9 cells and Gefitinib-resistant H1975 cells. | Oncogenesis

Fig. 6: BTK inhibitor Acalabrutinib promotes the anti-proliferative effects of Gefitinib/Osimertinib in Gefitinib-sensitive PC-9 cells and Gefitinib-resistant H1975 cells.

From: Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma

Fig. 6

Cell viability after treatment with different concentrations of TKIs and Acalabrutinib was evaluated by SRB assay in PC-9 cells and H1975 cells. A PC-9: Gefitinib + Acalabrutinib; B H1975: Gefitinib + Acalabrutinib; C H1975: Osimertinib + Acalabrutinib. Combination index (CI) for drugs and isobolograms were used to illustrate the synergistic effects of each two drugs in PC-9 cells and H1975 cells. D PC-9: Gefitinib + Acalabrutinib; E H1975: Gefitinib + Acalabrutinib; F H1975: Osimertinib + Acalabrutinib. G Colony formation assay showed colony number of PC-9 and H1975 cells after treatment of Acalabrutinib with or without Gefitinib significantly decreased. *p < 0.05, **p < 0.01.

Back to article page